Vivebiotech
A GMP contract development and manufacturing organization (CDMO) specialized in Lentiviral vectors.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | €40.0m | Growth Equity VC | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 11275 % | (26 %) | 150 % | 127 % | 46 % | 30 % | 69 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 9 % | (70 %) | (3 %) | 21 % | 22 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 7 % | (54 %) | (14 %) | 12 % | 14 % | (9 %) | 1 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
VIVEbiotech is a Contract Development and Manufacturing Organization (CDMO) that specializes in the production of lentiviral vectors, a critical component in gene and cell therapies. The company provides its services to the biopharmaceutical industry, assisting clients from the early stages of research and preclinical development through to GMP-compliant manufacturing for clinical and commercial use.
Operating under both European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) standards, VIVEbiotech positions itself as a dedicated partner in the advanced therapies field. Its business model is centered on providing comprehensive manufacturing services and expertise in lentiviral vector technology. The company generates revenue by contracting its development and manufacturing capabilities to biotech and pharmaceutical companies that are developing cell and gene therapies.
Keywords: lentiviral vectors, CDMO, gene therapy, cell therapy, GMP manufacturing, biopharmaceutical, viral vectors, drug development, clinical trials, EMA